Dyne Therapeutics, Inc. Operating Lease, Expense
Dyne Therapeutics, Inc. (DYN) reported Operating Lease, Expense of $2.10 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-10.
Discontinued › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2022-03-10
- Dyne Therapeutics, Inc. operating lease, expense for the quarter ending 2021-12-31 was $1.50M, a 275.00% increase year-over-year.
- Dyne Therapeutics, Inc. operating lease, expense for the quarter ending 2021-09-30 was $200.00K, a 0.00% change year-over-year.
- Dyne Therapeutics, Inc. operating lease, expense for the quarter ending 2021-06-30 was $200.00K, a 0.00% change year-over-year.
- Dyne Therapeutics, Inc. operating lease, expense for the quarter ending 2021-03-31 was $200.00K, a 0.00% change year-over-year.
- Dyne Therapeutics, Inc. operating lease, expense for fiscal 2021 was $2.10M, a 162.50% increase from fiscal 2020.
- Dyne Therapeutics, Inc. operating lease, expense for fiscal 2020 was $800.00K, a 14.29% increase from fiscal 2019.
- Dyne Therapeutics, Inc. operating lease, expense for fiscal 2019 was $700.00K.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 9 month as first filed | Operating Lease, Expense 12 month |
|---|---|---|---|---|---|
| 2021-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $1.70M derived: sum of 2 quarters · filed 2022-03-10 | $1.90M derived: sum of 3 quarters · filed 2022-03-10 | $2.10M 10-K · filed 2022-03-10 | |
| 2021-09-30 | $200.00K 10-Q · filed 2021-11-04 | $400.00K derived: sum of 2 quarters · filed 2021-11-04 | $600.00K 10-Q · filed 2021-11-04 | $1.00M derived: sum of 4 quarters · filed 2022-03-10 | |
| 2021-06-30 | $200.00K 10-Q · filed 2021-08-05 | $400.00K 10-Q · filed 2021-08-05 | $800.00K derived: sum of 3 quarters · filed 2022-03-10 | $1.00M derived: sum of 4 quarters · filed 2022-03-10 | |
| 2021-03-31 | $200.00K 10-Q · filed 2021-05-06 | $600.00K derived: sum of 2 quarters · filed 2022-03-10 | $800.00K derived: sum of 3 quarters · filed 2022-03-10 | $1.00M derived: sum of 4 quarters · filed 2022-03-10 | |
| 2020-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $600.00K derived: sum of 2 quarters · filed 2022-03-10 | $800.00K derived: sum of 3 quarters · filed 2022-03-10 | $800.00K 10-K · filed 2022-03-10 | |
| 2020-09-30 | $200.00K 10-Q · filed 2021-11-04 | $400.00K derived: sum of 2 quarters · filed 2021-11-04 | $400.00K 10-Q · filed 2021-11-04 | $200.00K 10-Q · filed 2020-11-05 | $900.00K derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $200.00K 10-Q · filed 2021-08-05 | $400.00K 10-Q · filed 2021-08-05 | $700.00K derived: sum of 3 quarters · filed 2021-08-05 | $1.10M derived: sum of 4 quarters · filed 2021-08-05 | |
| 2020-03-31 | $200.00K 10-Q · filed 2021-05-06 | $500.00K derived: sum of 2 quarters · filed 2021-05-06 | $900.00K derived: sum of 3 quarters · filed 2021-05-06 | ||
| 2019-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $700.00K derived: sum of 2 quarters · filed 2021-03-04 | $700.00K 10-K · filed 2021-03-04 | ||
| 2019-09-30 | $400.00K 10-Q · filed 2020-11-05 | $400.00K 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |